A Prospective Natural History Study of Inclusion Body Myositis: Implications for Clinical Trials
Affiliations
Eleven patients with untreated inclusion body myositis (IBM) were prospectively studied during a 6-month period that included muscle strength, lean body mass, and muscle mass measurements. There was an overall quantifiable mean decline in percent of predicted normal muscle strength of 4% from baseline in a 6-month period, but one third of patients showed no change or slight improvements in strength. Short-term treatment trials in IBM will require large numbers of patients to detect slowing, arrest, or even slight improvement in muscle strength.
Clinical Subgroups and Factors Associated With Progression in Patients With Inclusion Body Myositis.
Michelle E, Pinal-Fernandez I, Casal-Dominguez M, Albayda J, Paik J, Tiniakou E Neurology. 2023; 100(13):e1406-e1417.
PMID: 36690456 PMC: 10065210. DOI: 10.1212/WNL.0000000000206777.
Treatment for inclusion body myositis.
Rose M, Jones K, Leong K, Walter M, Miller J, Dalakas M Cochrane Database Syst Rev. 2022; 7:CD001555.
PMID: 35658164 PMC: 9645777. DOI: 10.1002/14651858.CD001555.pub5.
Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.
Shelly S, Mielke M, Mandrekar J, Milone M, Ernste F, Naddaf E Neurology. 2021; 96(21):e2653-e2661.
PMID: 33879596 PMC: 8205447. DOI: 10.1212/WNL.0000000000012004.
Oldroyd A, Lilleker J, Williams J, Chinoy H, Miller J Muscle Nerve. 2020; 62(1):76-82.
PMID: 32134516 PMC: 8629114. DOI: 10.1002/mus.26859.
Inclusion body myositis: therapeutic approaches.
Aggarwal R, Oddis C Degener Neurol Neuromuscul Dis. 2019; 2:43-52.
PMID: 30890877 PMC: 6065613. DOI: 10.2147/DNND.S19899.